Targeting syndecans: a promising strategy for the treatment of cancer

Bibliography

• Lambaerts K, Wilcox-Adelman SA, Zimmermann P. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 2009;21:662-9
   PubMed Web of Science ®Google Scholar
• Multhaupt HA, Yoneda A, Whiteford JR, et al. Syndecan signaling: When, where and why? J Physiol Pharmacol 2009;4:31-8
   Google Scholar
• Choi Y, Chung H, Jung H, et al. Syndecans as cell surface receptors: Unique structure equates with functional diversity. Matrix Biol 2011;30:93-9
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Jang B, Yi JY, et al. Syndecans play dual roles as cell adhesion receptors and docking receptors. FEBS Lett 2012;586:2207-11
   PubMed Web of Science ®Google Scholar
• Xian X, Gopal S, Couchman JR. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res 2010;339:31-46
   PubMedGoogle Scholar
• Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 2010;26:89-114
   PubMed Web of Science ®Google Scholar
• Tkachenko E, Rhodes JM, Simons M. Syndecans: New kids on the signaling block. Circ Res 2005;96:488-500
   PubMed Web of Science ®Google Scholar
• Day R, Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999;354:62-5
   PubMed Web of Science ®Google Scholar
• Bayer-Garner IB, Reed JA. Immunolabeling pattern of syndecan-1 expression may distinguish pagetoid bowen's disease, extramammary paget's disease, and pagetoid malignant melanoma in situ. J Cutan Pathol 2004;31:169-73
   PubMedGoogle Scholar
• Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20-9
   PubMed Web of Science ®Google Scholar
• Chen D, Adenekan B, Chen L, et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004;63:402-7
   PubMedGoogle Scholar
• Edwards IJ. Proteoglycans in prostate cancer. Nat Rev Urol 2012;9:196-206
   PubMed Web of Science ®Google Scholar
• Shimada K, Nakamura M, De Velasco MA, et al. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009;100:1248-54
   PubMedGoogle Scholar
• Kurokawa H, Zhang M, Matsumoto S, et al. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma. J Oral Pathol Med 2006;35:301-6
   PubMedGoogle Scholar
• Sanderson RD, Yang Y. Syndecan-1: A dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008;25:149-59
   PubMedGoogle Scholar
• Metwaly HA, Al-Gayyar MM, Eletreby S, et al. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm 2012;80:179-88
   PubMedGoogle Scholar
• Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997;74:482-91
   PubMedGoogle Scholar
• Pap Z, Pavai Z, Denes L, et al. An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, syndecan-1, ets-1. Pathol Oncol Res 2009;15:579-87
   PubMedGoogle Scholar
• Giordano RJ. Heparanase-2 and syndecan-1 in colon cancer: The ugly ducklings or the beautiful swans? Eur J Gastroenterol Hepatol 2008;20:716-18
   PubMedGoogle Scholar
• Chen E, Hermanson S, Ekker SC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 2004;103:1710-19
   PubMed Web of Science ®Google Scholar
• Arrington CB, Yost HJ. Extra-embryonic syndecan 2 regulates organ primordia migration and fibrillogenesis throughout the zebrafish embryo. Development 2009;136:3143-52
   Google Scholar
• Munesue S, Kusano Y, Oguri K, et al. The role of syndecan-2 in regulation of actin-cytoskeletal organization of lewis lung carcinoma-derived metastatic clones. Biochem J 2002;363:201-9
   PubMedGoogle Scholar
• Han I, Park H, Oh ES. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 2004;3:319-26
   Google Scholar
• Park H, Han I, Kwon HJ, et al. Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells. Cancer Res 2005;65:9899-905
   PubMedGoogle Scholar
• Kim Y, Park H, Lim Y, et al. Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene 2003;22:826-30
   PubMedGoogle Scholar
• Fears CY, Gladson CL, Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 2006;281:14533-6
   PubMed Web of Science ®Google Scholar
• Munesue S, Yoshitomi Y, Kusano Y, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007;282:28164-74
   PubMed Web of Science ®Google Scholar
• Diamantopoulou Z, Kitsou P, Menashi S, et al. Loss of receptor protein tyrosine phosphatase beta/zeta (RPTP beta/zeta) promotes prostate cancer metastasis. J Biol Chem 2012;287:40339-49
   PubMedGoogle Scholar
• Davies EJ, Blackhall FH, Shanks JH, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004;10:5178-86
   PubMed Web of Science ®Google Scholar
• Whitworth MK, Backen AC, Clamp AR, et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005;11:4282-8
   PubMed Web of Science ®Google Scholar
• Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7
   PubMed Web of Science ®Google Scholar
• Park H, Kim Y, Lim Y, et al. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002;277:29730-6
   PubMedGoogle Scholar
• Huang W, Chiquet-Ehrismann R, Moyano JV, et al. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001;61:8586-94
   PubMed Web of Science ®Google Scholar
• Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009;30:397-407
   PubMed Web of Science ®Google Scholar
• Lee JH, Park H, Chung H, et al. Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem 2009;284:27167-75
   PubMedGoogle Scholar
• Chung H, Lee JH, Jeong D, et al. Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression. J Biol Chem 2012;287:19326-35
   PubMedGoogle Scholar
• Dieudonne FX, Marion A, Hay E, et al. High wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cell. Cancer Res 2010;70:5399-408
   PubMedGoogle Scholar
• Dieudonne FX, Marion A, Marie PJ, et al. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice. J Bone Miner Res 2012;27:2118-29
   PubMedGoogle Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332-43
   PubMed Web of Science ®Google Scholar
• Badiola I, Olaso E, Crende O, et al. Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut 2012;61:1465-72
   PubMed Web of Science ®Google Scholar
• Conklin MW, Eickhoff JC, Riching KM, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011;178:1221-32
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun H, Owens RT, et al. Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 2010;12:826-36
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kurokawa T, Nishikawa Y, et al. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin. Int J Oncol 2008;32:673-81
   PubMedGoogle Scholar
• Modrowski D, Orosco A, Thevenard J, et al. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: Implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone 2005;37:180-9
   PubMed Web of Science ®Google Scholar
• Baljinnyam E, Iwatsubo K, Kurotani R, et al. Epac increases melanoma cell migration by a heparan sulfate-related mechanism. Am J Physiol Cell Physiol 2009;297:C802-13
   PubMedGoogle Scholar
• Yao J, Ma Q, Wang L, et al. Pleiotrophin expression in human pancreatic cancer and its correlation with clinicopathological features, perineural invasion, and prognosis. Dig Dis Sci 2009;54:895-901
   PubMedGoogle Scholar
• Chalkiadaki G, Nikitovic D, Berdiaki A, et al. Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 2009;41:1323-31
   PubMedGoogle Scholar
• Vuoriluoto K, Hognas G, Meller P, et al. Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through alpha2beta1 integrin and MT1-MMP. Matrix Biol 2011;30:207-17
   PubMedGoogle Scholar
• Chiron D, Maiga S, Descamps G, et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012;48:247-53
   PubMedGoogle Scholar
• Lamorte S, Ferrero S, Aschero S, et al. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 2012;26:1081-90
   PubMedGoogle Scholar
• Moreaux J, Sprynski AC, Dillon SR, et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 2009;83:119-29
   PubMed Web of Science ®Google Scholar
• Oh JH, Lee HS, Park SH, et al. Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model. Int J Gynecol Cancer 2010;20:751-6
   PubMed Web of Science ®Google Scholar
• Oh JH, Kim JH, Ahn HJ, et al. Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol Oncol 2009;114:509-15
   PubMed Web of Science ®Google Scholar
• Beauvais DM, Ell BJ, McWhorter AR, et al. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009;206:691-705
   PubMed Web of Science ®Google Scholar
• Saito Y, Owaki T, Matsunaga T, et al. Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4. J Biol Chem 2010;285:7006-15
   PubMedGoogle Scholar
• Vuoriluoto K, Jokinen J, Kallio K, et al. Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp Cell Res 2008;314:3369-81
   PubMedGoogle Scholar
• Choi S, Kim Y, Park H, et al. Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 2009;384:231-5
   PubMedGoogle Scholar
• Ryu HY, Lee J, Yang S, et al. Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem 2009;284:35692-701
   PubMedGoogle Scholar
• De Oliveira T, Abiatari I, Raulefs S, et al. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Mol Cancer 2012;11:19
   PubMed Web of Science ®Google Scholar
• Huang X, Xiao DW, Xu LY, et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep 2009;21:1123-9
   PubMedGoogle Scholar
• Hrabar D, Aralica G, Gomercic M, et al. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma. Anticancer Res 2010;30:2749-53
   PubMedGoogle Scholar
• Popovic A, Demirovic A, Spajic B, et al. Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis 2010;13:78-82
   PubMedGoogle Scholar
• Nord H, Segersten U, Sandgren J, et al. Focal amplifications are associated with high grade and recurrences in stage ta bladder carcinoma. Int J Cancer 2010;126:1390-402
   PubMed Web of Science ®Google Scholar
• O'Connell MP, Fiori JL, Kershner EK, et al. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J Biol Chem 2009;284:28704-12
   PubMed Web of Science ®Google Scholar
• Chang SC, Mulloy B, Magee AI, et al. Two distinct sites in sonic hedgehog combine for heparan sulfate interactions and cell signaling functions. J Biol Chem 2011;286:44391-402
   PubMed Web of Science ®Google Scholar
• Juric V, Chen CC, Lau LF. TNFalpha-induced apoptosis enabled by CCN1/CYR61: Pathways of reactive oxygen species generation and cytochrome c release. PLoS One 2012;7:e31303
   Google Scholar
• Wang H, Leavitt L, Ramaswamy R, et al. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: Regulation of ErbB2-mediated integrin activation. J Biol Chem 2010;285:13569-79
   PubMedGoogle Scholar
• Zong F, Fthenou E, Wolmer N, et al. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One 2009;4-e7346
   Google Scholar
• Zong F, Fthenou E, Castro J, et al. Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains. Cell Prolif 2010;43:29-40
   PubMedGoogle Scholar
• Zong F, Fthenou E, Mundt F, et al. Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS One 2011;6:e14816
   Google Scholar
• Purushothaman A, Hurst DR, Pisano C, et al. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 2011;286:30377-83
   PubMedGoogle Scholar
• Lee H, Kim Y, Choi Y, et al. Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1. Biochem Biophys Res Commun 2011;409:148-53
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim H, Chung H, et al. Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated rac activation. Biochem Biophys Res Commun 2010;391:921-5
   PubMed Web of Science ®Google Scholar
• Simons M, Horowitz A. Syndecan-4-mediated signalling. Cell Signal 2001;13:855-62
   PubMed Web of Science ®Google Scholar
• Ridgway LD, Wetzel MD, Ngo JA, et al. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res 2012;10:689-702
   PubMed Web of Science ®Google Scholar
• Keller-Pinter A, Bottka S, Timar J, et al. Syndecan-4 promotes cytokinesis in a phosphorylation-dependent manner. Cell Mol Life Sci 2010;67:1881-94
   PubMed Web of Science ®Google Scholar
• Reijmers RM, Groen RW, Rozemuller H, et al. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 2010;115:601-4
   PubMedGoogle Scholar
• Bret C, Hose D, Reme T, et al. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 2009;145:350-68
   PubMedGoogle Scholar
• Brule S, Friand V, Sutton A, et al. Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells. Biochim Biophys Acta 2009;1790:1643-50
   PubMedGoogle Scholar
• Kumarasuriyar A, Lee I, Nurcombe V, et al. De-sulfation of MG-63 cell glycosaminoglycans delays in vitro osteogenesis, up-regulates cholesterol synthesis and disrupts cell cycle and the actin cytoskeleton. J Cell Physiol 2009;219:572-83
   PubMedGoogle Scholar
• Choi S, Lee H, Choi JR, et al. Shedding; towards a new paradigm of syndecan function in cancer. BMB Rep 2010;43:305-10
   PubMed Web of Science ®Google Scholar
• Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: The multiple roles of syndecan shedding. FEBS J 2010;277:3876-89
   PubMed Web of Science ®Google Scholar
• Kim JM, Lee JA, Cho IS, et al. Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: A single institution study. Korean J Hematol 2010;45:115-19
   PubMedGoogle Scholar
• Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002;62:5210-17
   PubMed Web of Science ®Google Scholar
• Purushothaman A, Uyama T, Kobayashi F, et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010;115:2449-57
   PubMedGoogle Scholar
• Peretti T, Waisberg J, Mader AM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol 2008;20:756-65
   PubMedGoogle Scholar
• Peterfia B, Fule T, Baghy K, et al. Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2. PLoS One 2012;7:e39474
   PubMed Web of Science ®Google Scholar
• Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the. heparanase/syndecan-1 axis. Clin Cancer Res 2011;17:1382-93
   PubMed Web of Science ®Google Scholar
• Su G, Blaine SA, Qiao D, et al. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res 2008;68:9558-65
   PubMedGoogle Scholar
• Aragao AZ, Belloni M, Simabuco FM, et al. Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration. PLoS One 2012;7:e43521
   Google Scholar
• Whiteford JR, Xian X, Chaussade C, et al. Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol Biol Cell 2011;22:3609-24
   PubMedGoogle Scholar
• Fitzgerald ML, Wang Z, Park PW, et al. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000;148:811-24
   PubMed Web of Science ®Google Scholar
• Ramani VC, Pruett PS, Thompson CA, et al. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 2012;287:9952-61
   PubMed Web of Science ®Google Scholar
• Dedes PG, Gialeli C, Tsonis AI, et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 2012;1820:1926-39
   PubMed Web of Science ®Google Scholar
• Paul AG, Sharma-Walia N, Chandran B. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: A potential chemotherapeutic modality for primary effusion lymphoma. PLoS One 2011;6:e24379
   Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028-37
   PubMed Web of Science ®Google Scholar
• Rousseau C, Ruellan AL, Bernardeau K, et al. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft. tumors. EJNMMI Res 2011;1:20
   PubMedGoogle Scholar
• Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004;104:3688-96
   PubMed Web of Science ®Google Scholar
• Charni F, Friand V, Haddad O, et al. Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 2009;1790:1314-26
   PubMedGoogle Scholar
• Dagouassat M, Suffee N, Hlawaty H, et al. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer 2010;126:1095-108
   PubMedGoogle Scholar
• Gong W, Liu Y, Huang B, et al. Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 2008;367:144-9
   PubMed Web of Science ®Google Scholar
• Siqueira AS, Gama-de-Souza LN, Arnaud MV, et al. Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and beta1 integrin. Tumour Biol 2010;31:46-58
   Google Scholar
• Gama-de-Souza LN, Cyreno-Oliveira E, Freitas VM, et al. Adhesion and protease activity in cell lines from human salivary gland tumors are regulated by the laminin-derived peptide AG73, syndecan-1 and beta1 integrin. Matrix Biol 2008;27:402-19
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Youssefian LE, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011;118:5189-200
   PubMed Web of Science ®Google Scholar
• Evans RP, Naber C, Steffler T, et al. The selective aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140:295-302
   PubMed Web of Science ®Google Scholar
• Ramya D, Siddikuzzaman Grace VM. Effect of all-trans retinoic acid (ATRA) on syndecan-1 expression and its chemoprotective effect in benzo(alpha)pyrene-induced lung cancer mice model. Immunopharmacol Immunotoxicol 2012;34:1020-7
   PubMed Web of Science ®Google Scholar